CompletedPhase 2

Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia

Australia23 participantsStarted 2009-03

Plain-language summary

The purpose of this study is to determine whether KAI-1678 is effective in the treatment of postherpetic neuralgia pain

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * diagnosis of PHN with pain for at least 3 months after segmental herpes zoster eruption * pain score at least 4 on 11-point numerical rating scale (0-10) * stable doses of analgesic medications for at least 1 month" Exclusion Criteria: * diagnosis of PHN with pain for at least 3 months after segmental herpes zoster eruption * pain score at least 4 on 11-point numerical rating scale (0-10) * stable doses of analgesic medications for at least 1 month"

What they're measuring

The effect of KAI-1678 on mean change from baseline in pain intensity at 6 hours (PID 6).

Timeframe: Day 1

Trial details

NCT IDNCT01106716

SponsorKAI Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-03

View on ClinicalTrials.gov More Postherpetic Neuralgia trials